Literature DB >> 31155227

Type I interferon signaling, regulation and gene stimulation in chronic virus infection.

Sabelo Lukhele1, Giselle M Boukhaled1, David G Brooks2.   

Abstract

Type I Interferons (IFN-I) mediate numerous immune interactions during viral infections, from the establishment of an antiviral state to invoking and regulating innate and adaptive immune cells that eliminate infection. While continuous IFN-I signaling plays critical roles in limiting virus replication during both acute and chronic infections, sustained IFN-I signaling also leads to chronic immune activation, inflammation and, consequently, immune exhaustion and dysfunction. Thus, an understanding of the balance between the desirable and deleterious effects of chronic IFN-I signaling will inform our quest for IFN-based therapies for chronic viral infections as well as other chronic diseases, including cancer. As such the factors involved in induction, propagation and regulation of IFN-I signaling, from the initial sensing of viral nucleotides within the cell to regulatory downstream signaling factors and resulting IFN-stimulated genes (ISGs) have received significant research attention. This review summarizes recent work on IFN-I signaling in chronic infections, and provides an update on therapeutic approaches being considered to counter such infections.
Copyright © 2019 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Adaptive immunity; Chronic virus infection; Exhaustion; IRF; ISG; Immune response; Innate immunity; Interferon; Interferon regulatory factor; Interferon stimulatory gene; T cell

Mesh:

Substances:

Year:  2019        PMID: 31155227      PMCID: PMC8029807          DOI: 10.1016/j.smim.2019.05.001

Source DB:  PubMed          Journal:  Semin Immunol        ISSN: 1044-5323            Impact factor:   11.130


  221 in total

1.  STING agonist formulated cancer vaccines can cure established tumors resistant to PD-1 blockade.

Authors:  Juan Fu; David B Kanne; Meredith Leong; Laura Hix Glickman; Sarah M McWhirter; Edward Lemmens; Ken Mechette; Justin J Leong; Peter Lauer; Weiqun Liu; Kelsey E Sivick; Qi Zeng; Kevin C Soares; Lei Zheng; Daniel A Portnoy; Joshua J Woodward; Drew M Pardoll; Thomas W Dubensky; Young Kim
Journal:  Sci Transl Med       Date:  2015-04-15       Impact factor: 17.956

Review 2.  Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy.

Authors:  Padmanee Sharma; Siwen Hu-Lieskovan; Jennifer A Wargo; Antoni Ribas
Journal:  Cell       Date:  2017-02-09       Impact factor: 41.582

3.  CD8+ T Cell Priming in Established Chronic Viral Infection Preferentially Directs Differentiation of Memory-like Cells for Sustained Immunity.

Authors:  Laura M Snell; Bethany L MacLeod; Jaclyn C Law; Ivan Osokine; Heidi J Elsaesser; Kebria Hezaveh; Russell J Dickson; Marc A Gavin; Cynthia J Guidos; Tracy L McGaha; David G Brooks
Journal:  Immunity       Date:  2018-10-09       Impact factor: 31.745

4.  Structurally similar but functionally distinct factors, IRF-1 and IRF-2, bind to the same regulatory elements of IFN and IFN-inducible genes.

Authors:  H Harada; T Fujita; M Miyamoto; Y Kimura; M Maruyama; A Furia; T Miyata; T Taniguchi
Journal:  Cell       Date:  1989-08-25       Impact factor: 41.582

5.  Double-stranded RNA deaminase ADAR1 increases host susceptibility to virus infection.

Authors:  Yongzhan Nie; Graeme L Hammond; Jing-Hua Yang
Journal:  J Virol       Date:  2006-11-01       Impact factor: 5.103

6.  The interferon-induced protein BST-2 restricts HIV-1 release and is downregulated from the cell surface by the viral Vpu protein.

Authors:  Nanette Van Damme; Daniel Goff; Chris Katsura; Rebecca L Jorgenson; Richard Mitchell; Marc C Johnson; Edward B Stephens; John Guatelli
Journal:  Cell Host Microbe       Date:  2008-03-13       Impact factor: 21.023

7.  Interferon alpha antagonizes STAT3 and SOCS3 signaling triggered by hepatitis C virus.

Authors:  Lan-Juan Zhao; Sheng-Fei He; Wen Wang; Hao Ren; Zhong-Tian Qi
Journal:  Cytokine       Date:  2016-03-03       Impact factor: 3.861

8.  A diverse range of gene products are effectors of the type I interferon antiviral response.

Authors:  John W Schoggins; Sam J Wilson; Maryline Panis; Mary Y Murphy; Christopher T Jones; Paul Bieniasz; Charles M Rice
Journal:  Nature       Date:  2011-04-10       Impact factor: 49.962

9.  Interplay between regulatory T cells and PD-1 in modulating T cell exhaustion and viral control during chronic LCMV infection.

Authors:  Pablo Penaloza-MacMaster; Alice O Kamphorst; Andreas Wieland; Koichi Araki; Smita S Iyer; Erin E West; Leigh O'Mara; Shu Yang; Bogumila T Konieczny; Arlene H Sharpe; Gordon J Freeman; Alexander Y Rudensky; Rafi Ahmed
Journal:  J Exp Med       Date:  2014-08-11       Impact factor: 14.307

10.  HCFC2 is needed for IRF1- and IRF2-dependent Tlr3 transcription and for survival during viral infections.

Authors:  Lei Sun; Zhengfan Jiang; Victoria A Acosta-Rodriguez; Michael Berger; Xin Du; Jin Huk Choi; Jianhui Wang; Kuan-Wen Wang; Gokhul K Kilaru; Jennifer A Mohawk; Jiexia Quan; Lindsay Scott; Sara Hildebrand; Xiaohong Li; Miao Tang; Xiaoming Zhan; Anne R Murray; Diantha La Vine; Eva Marie Y Moresco; Joseph S Takahashi; Bruce Beutler
Journal:  J Exp Med       Date:  2017-10-02       Impact factor: 14.307

View more
  11 in total

Review 1.  New immunodeficiency syndromes that help us understand the IFN-mediated antiviral immune response.

Authors:  Huie Jing; Helen C Su
Journal:  Curr Opin Pediatr       Date:  2019-12       Impact factor: 2.856

2.  MST4 negatively regulates type I interferons production via targeting MAVS-mediated pathway.

Authors:  Wei Liu; Zhenling Ma; Yaru Wu; Cui Yuan; Yanyan Zhang; Zeyang Liang; Yu Yang; Wenwen Zhang; Pengtao Jiao
Journal:  Cell Commun Signal       Date:  2022-07-12       Impact factor: 7.525

3.  Targeted Modulation of Interferon Response-Related Genes with IFN-Alpha/Lambda Inhibition.

Authors:  Debpali Sur; Katerina Leonova; Bar Levi; Shany Ivon Markowitz; Raichel Cohen-Harazi; Ilya Gitlin; Katerina Gurova; Andrei Gudkov; Albert Pinhasov; Igor Koman; Elimelech Nesher
Journal:  Int J Mol Sci       Date:  2022-06-29       Impact factor: 6.208

4.  Early innate and adaptive immune perturbations determine long-term severity of chronic virus and Mycobacterium tuberculosis coinfection.

Authors:  Wenxi Xu; Laura M Snell; Mengdi Guo; Giselle Boukhaled; Bethany L Macleod; Ming Li; Michael V Tullius; Cynthia J Guidos; Ming-Sound Tsao; Maziar Divangahi; Marcus A Horwitz; Jun Liu; David G Brooks
Journal:  Immunity       Date:  2021-01-29       Impact factor: 31.745

Review 5.  Opposing Roles of Type I Interferons in Cancer Immunity.

Authors:  Giselle M Boukhaled; Shane Harding; David G Brooks
Journal:  Annu Rev Pathol       Date:  2020-12-02       Impact factor: 23.472

6.  Transcriptional insights into the CD8+ T cell response in mono-HIV and HCV infection.

Authors:  Si-Yao Li; Zi-Ning Zhang; Yong-Jun Jiang; Ya-Jing Fu; Hong Shang
Journal:  J Transl Med       Date:  2020-02-24       Impact factor: 5.531

Review 7.  Type I Interferon (IFN)-Regulated Activation of Canonical and Non-Canonical Signaling Pathways.

Authors:  Candice Mazewski; Ricardo E Perez; Eleanor N Fish; Leonidas C Platanias
Journal:  Front Immunol       Date:  2020-11-23       Impact factor: 7.561

Review 8.  Type I Interferons and Malaria: A Double-Edge Sword Against a Complex Parasitic Disease.

Authors:  Xiao He; Lu Xia; Keyla C Tumas; Jian Wu; Xin-Zhuan Su
Journal:  Front Cell Infect Microbiol       Date:  2020-12-02       Impact factor: 5.293

9.  Landscape of Peripheral Blood Mononuclear Cells and Soluble Factors in Severe COVID-19 Patients With Pulmonary Fibrosis Development.

Authors:  Zhuolin Wang; Yang Zhang; Rirong Yang; Yujia Wang; Jiapei Guo; Ruya Sun; Yuan Zhou; Li Su; Qing Ge; Yingmei Feng
Journal:  Front Immunol       Date:  2022-04-26       Impact factor: 8.786

Review 10.  Type I interferons and related pathways in cell senescence.

Authors:  Steven M Frisch; Ian P MacFawn
Journal:  Aging Cell       Date:  2020-09-12       Impact factor: 9.304

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.